drugset / Trial / NCT00035529
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Timeline
- Start
- 2001-11
- Primary completion
- 2003-12
- Completion
- 2003-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abatacept | Other / unclassified | 2 mg/kg | Intravenous |
| Comparator | Abatacept | Other / unclassified | 10 mg/kg | Intravenous |